In summary, reports showing that epoetin alfa has a beneficial effect on QOL in anemic patients with cancer are strongly supported by existing data. Further robust research to better define the value of QOL improvement due to epoetin alfa in cancer patients, as Bottomley and his colleagues recommended in their review, would certainly strengthen these results.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Jan 1 2002|
ASJC Scopus subject areas